Urolithin A Database Methodology & Scoring
The scoring system rewards information that can be checked. It does not reward a product for merely sounding expensive, scientific or mitochondrial.
Source hierarchy
- Current official manufacturer product pages.
- Official brand collections or official educational pages when the product page is unavailable.
- Independent structured product data when official product details cannot be verified.
- Major marketplace listings, clearly labeled as marketplace evidence.
- Ingredient-supplier pages only for raw-material benchmarks, never presented as consumer SKUs.
Transparency Score /10
Rewards active-dose disclosure, serving clarity, current price capture, visible or stated COA availability, testing disclosure, certifications and ingredient-identity detail. It measures auditability, not efficacy.
Testing Transparency Score /10
Separates testing and certification from the rest of the product. Visible batch documentation scores more strongly than a generic “lab tested” statement. Certification does not prove clinical effectiveness.
Evidence Match Score /10
Measures how cleanly the commercial product maps to the evidence being used to discuss it. Mitopure formats score highly because human studies directly evaluate the branded ingredient and commonly used 500 mg/1,000 mg dosing context. Generic products can still map reasonably well to ingredient-level research, but should not inherit Mitopure-specific certifications or finished-product evidence.
Urolithin A Value Score /10
Calculated only for full-size consumer products where a current price and Urolithin A dose are both captured. Lower normalized cost per 500 mg improves the value score, but value is kept separate from testing and evidence quality.
Stack Complexity /5
Single-ingredient products score low complexity. Multi-active formulas score higher. Complexity is descriptive, not inherently good or bad; it simply increases the number of assumptions required when evaluating evidence.
Source hierarchy
Official manufacturer pages are preferred for current product specifications. Official brand education pages, independent structured product data, and major marketplaces are used only when clearly labeled.
Snapshot dates
Product facts are time-sensitive and should be rechecked when formulas, prices, certifications, or availability change.
Field definitions
Dose is the stated Urolithin A amount per serving where verified. Price is the captured one-time price unless otherwise noted. Testing and COA fields are recorded only when supported by the source.
Transparency scoring
Transparency rewards auditable product information and must not be interpreted as clinical efficacy.
Testing scoring
Testing Transparency separates COA visibility, third-party testing, and formal certification from the rest of the product.
Evidence-match scoring
Evidence Match describes how cleanly a commercial product maps to the evidence being cited.
Value scoring
Value is calculated only where a full-size consumer product has enough verified price and dose data for normalized cost per 500 mg.
Complexity scoring
Formula complexity is descriptive, not inherently positive or negative. More ingredients increase the burden of proof.
Update trigger 1
For Urolithin A Database Methodology & Scoring, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 2
For Urolithin A Database Methodology & Scoring, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 3
For Urolithin A Database Methodology & Scoring, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 4
For Urolithin A Database Methodology & Scoring, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 5
For Urolithin A Database Methodology & Scoring, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 6
For Urolithin A Database Methodology & Scoring, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 7
For Urolithin A Database Methodology & Scoring, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 8
For Urolithin A Database Methodology & Scoring, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 9
For Urolithin A Database Methodology & Scoring, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 10
For Urolithin A Database Methodology & Scoring, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 11
For Urolithin A Database Methodology & Scoring, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 12
For Urolithin A Database Methodology & Scoring, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.